Trial Profile

First-in-human trial of NVG-2089

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 21 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NVG 2089 (Primary)
Indications Autoimmune disorders; Myositis
Focus Adverse reactions; First in man

Most Recent Events

14 May 2025 According to a Nuvig Therapeutics media release, the company will present results from a Phase 1 study of NVG-2089 in healthy volunteers at the 2025 Peripheral Nerve Society (PNS) Annual Meeting
05 Dec 2024 Results presented in a Nuvig Therapeutics Media Release.
05 Dec 2024 Status changed to active, no longer recruiting, according to a Nuvig Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com